Equity Overview
Price & Market Data
Price: $1.40
Daily Change: -$0.08 / 5.71%
Daily Range: $1.34 - $1.59
Market Cap: $33,151,360
Daily Volume: 525,999
Performance Metrics
1 Week: -2.11%
1 Month: 14.88%
3 Months: 33.65%
6 Months: 28.70%
1 Year: 4.51%
YTD: 18.80%
Company Details
Employees: 36
Sector: Health technology
Industry: Biotechnology
Country:
Details
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which is in phase I/II clinical trial for the treatment of Basal thumb osteoarthritis; and ENX-CL-06-001 to treat Psoriatic arthritis and is in phase I/II clinical trial. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Ness Ziona, Israel.